Figure 1.

Represents patients with breast carcinoma eligible for therapy based on biomarker status. Patients with breast carcinoma were stratified into HR+/HER2−, HER2+, and triple‐negative breast cancer (TNBC) groups and tested with standard of care diagnostics. Next, in the HR+/HER2− cohort, patients were stratified into PIK3CA+ versus PIK3CA− groups, and patients with TNBC were stratified into programmed death‐ligand 1 (PD‐L1) + versus PD‐L1− groups. The remaining patients that were not positive for PIK3CA and/or PD‐L1 were stratified into whether they had a BRCA1/2 mutation. Last, the patients without positivity in one of the above‐mentioned biomarkers were examined for positivity in a biomarker that was clinically actionable or potentially clinically actionable.

Abbreviations: −, negative; +, positive; CDx, companion diagnostics; HR, hormone receptor.